| 1 | State of Arkansas As Engrossed: S1/16/25 S3/6/25 | |
|----------|-------------------------------------------------------------------------|----------|
| 2 | 95th General Assembly A Bill | |
| 3 | Regular Session, 2025SENATE BILL | . 6 |
| 4 | | |
| 5 | By: Senator B. King | |
| 6 | | |
| 7 | | |
| 8 | For An Act To Be Entitled | |
| 9 | AN ACT TO CREATE THE CRIMINAL OFFENSE OF VACCINE | |
| 10 | HARM; AND FOR OTHER PURPOSES. | |
| 11 | | |
| 12 | S1-4*41- | |
| 13 | Subtitle | |
| 14 | TO CREATE THE CRIMINAL OFFENSE OF | |
| 15 | VACCINE HARM. | |
| 16 | | |
| 17 | BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS: | |
| 18 | | 1 |
| 19 20 | SECTION 1. Arkansas Code Title 5, Chapter 63, Subchapter 2, is amende | a |
| 20 | to add an additional section to read as follows: | |
| 22 | <u>5-63-206. Vaccine harm.</u> (a) As used in this section: | |
| 22 | (1) "Executive officer" means a president, chair of an executiv | |
| 24 | committee, chief financial officer, or other individual with managerial | <u>c</u> |
| 25 | authority who performs similar functions to a president, chair of an | |
| 26 | executive committee, or chief financial officer; | |
| 27 | (2)(A) "Pharmaceutical company" means a business that is | |
| 28 | registered with the United States Food and Drug Administration to | |
| 29 | commercially research, develop, market, manufacture, and distribute | |
| 30 | prescription drugs. | |
| 31 | (B) "Pharmaceutical company" does not include a licensed, | |
| 32 | registered, or otherwise permitted healthcare provider or healthcare | |
| 33 | facility, such as a pharmacy, hospital, or pharmacist; and | |
| 34 | (3) "Vaccination" means the introduction of a vaccine into the | |
| 35 | body. | |
| 36 | (b) A person commits vaccine harm if: | |



| 1 | (1) The person is an executive officer for a pharmaceutical |
|----|-----------------------------------------------------------------------------|
| 2 | company and is eighteen (18) years of age or older; |
| 3 | (2) The person introduces a vaccine produced by the |
| 4 | pharmaceutical company into the market; |
| 5 | (3) The person knowingly hides, conceals, omits, or otherwise |
| 6 | withholds evidence, documentation, or information that the vaccine has |
| 7 | dangerous effects; |
| 8 | (4) Another person receives the vaccine in this state through a |
| 9 | vaccination containing the vaccine; and |
| 10 | (5) The vaccination causes the death of or serious physical |
| 11 | injury to the other person. |
| 12 | (c) Vaccine harm is an unclassified felony with a sentence of |
| 13 | imprisonment of not less than one (1) year and not more than life. |
| 14 | |
| 15 | SECTION 2. Arkansas Code Title 19, Chapter 5, Subchapter 12, is |
| 16 | amended to add an additional section to read as follows: |
| 17 | 19-5-1287. Vaccine Harm Offense Fund. |
| 18 | (a) There is created on the books of the Treasurer of State, the |
| 19 | Auditor of State, and the Chief Fiscal Officer of the State a miscellaneous |
| 20 | fund to be known as the "Vaccine Harm Offense Fund". |
| 21 | (b) The fund shall consist of: |
| 22 | (1) Federal funds received through a grant; |
| 23 | (2) Appropriations from the General Assembly; and |
| 24 | (3) Other revenues and funds authorized by law. |
| 25 | (c) The fund shall be used to provide funding and support for the |
| 26 | prosecution of the offense of vaccine harm under § 5-63-206. |
| 27 | |
| 28 | SECTION 3. DO NOT CODIFY. <u>Expiration date.</u> |
| 29 | (a) This act expires on December 31, 2026. |
| 30 | (b) On or after December 31, 2026, the Bureau of Legislative Research |
| 31 | or the Arkansas Code Revision Commission may remove from the Arkansas Code |
| 32 | the sections created in Sections 1 and 2 of this act. |
| 33 | (c) Any funds in the Vaccine Harm Offense Fund on December 31, 2026, |
| 34 | shall be transferred to the General Revenue Fund Account. |
| 35 | |
| 36 | /s/B. King |